Sanofi, Regeneron to Appeal Injunction Barring Sales of Cholesterol Drug in U.S.

January 12, 2017

Sanofi and Regeneron intend to appeal a federal court injunction banning the sale of their cholesterol drug Praluent after a judge found the companies infringed an Amgen patent covering Repatha.

Judge Sue Robinson for the District of Delaware issued the permanent injunction after concluding that Amgen’s Repatha patents are valid. The injunction takes effect 30 days from Jan. 5 to give Sanofi and Regeneron an opportunity to appeal the case or reach a settlement with Amgen.

In a statement, Sanofi said it continues to hold the position that Amgen’s patent claims are invalid. Regeneron and Sanofi plan to immediately file an appeal.

View today's stories